Viral Suppression in Children on ART Identified Via Quantitative HIV Antibody Levels
For children receiving , HIV-1-specific antibody levels can be useful markers for measuring viral suppression or for low residual cell-associated HIV-1 DNA levels.
For children receiving , HIV-1-specific antibody levels can be useful markers for measuring viral suppression or for low residual cell-associated HIV-1 DNA levels.
Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.
Once-daily single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in adults who have virologic suppression of HIV-1 infection has a high efficacy and safety profile.
Incidence of body fat redistribution/accumulation, pancreatic disorders, musculoskeletal disorders, IRIS, severe systemic rash, and HSR did not differ among common prescribed antiretrovirals.
Vitamin D deficiency is associated with increased risk for sepsis mortality in postmenopausal women, which was seen in all ages.
A combination single tablet once-a-day regimen of doravirine/lamivudine/tenofovir disoproxil fumarate demonstrated non-inferiority and no significant adverse events when compared with continuation of established antiretroviral therapy in adults infected with HIV-1.
The week 96 results of the DRIVE-AHEAD phase 3 noninferiority trial support noninferiority of doravirine to efavirenz in treatment-naive adults with HIV-1.
Children who are HIV-exposed, but uninfected, demonstrated a higher risk of adverse neurologic events during infancy and early childhood associated with ART exposure in-utero.
A recent meta-analysis and literature review found moderate evidence supporting an association between pain outcomes in people with HIV and several psychosocial factors.
Tenofovir diphosphate in dried blood spots was strongly associated with virologic suppression in those living with HIV on TDF-based therapies.